

The disclosure provides a binding molecule having (i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 159, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 160, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 161, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 162, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 163, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 164, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 165, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 166, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 167, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 168, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 169, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 170, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 171, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 172, and (ii) a light chain comprising the amino acid sequence of SEQ ID NO: 173.

15 In another aspect, the disclosure provides a binding molecule comprising at least one antigen binding site that binds specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and at least one antigen binding site that binds specifically to cadherin-17 (CDH17); wherein the molecule is bispecific and tetravalent; wherein the at least one antigen binding site that binds specifically to cadherin-17 (CDH17) is an immunoglobulin (Ig) molecule and the at least one antigen binding site that binds specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) comprises one or more scFv(s); and wherein the one or more scFv(s) is fused to the C-terminus of the heavy chain of the Ig molecule, wherein the binding molecule comprises (i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 159, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 160, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 161, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 163, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 164, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 166, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 167, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 168, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 169, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 170, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 171, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 172, and (ii) a light chain comprising the amino acid sequence of SEQ ID NO: 173.

The disclosure provides a binding molecule having (i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 174, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 175, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 176, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 177, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 178, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 179, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 180, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 181, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 182, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 183, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 184, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 185, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 186, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 187, and (ii) a light chain comprising the amino acid sequence of SEQ ID NO: 188.

15 In another aspect, the disclosure provides a binding molecule comprising at least one antigen binding site that binds specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and at least one antigen binding site that binds specifically to cadherin-17 (CDH17); wherein the molecule is bispecific and tetravalent; wherein the at least one antigen binding site that binds specifically to cadherin-17 (CDH17) is an immunoglobulin (Ig) molecule and the at least one antigen binding site that binds specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) comprises one or more scFv(s); and wherein the one or more scFv(s) is fused to the C-terminus of the heavy chain of the Ig molecule, wherein the binding molecule comprises (i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 174, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 175, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 176, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 178, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 179, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 181, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 182, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 183, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 184, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 185, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 186, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 187, and (ii) a light chain comprising the amino acid sequence of SEQ ID NO: 188.

The disclosure provides a binding molecule having (i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 189, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 190, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 191,

5 or a

heavy chain comprising the amino acid sequence of SEQ ID NO: 192, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 193, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 194, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 195, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 196, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 197, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 198, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 199, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 200, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 201, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 202, and (ii) a light chain comprising the amino acid sequence of SEQ ID NO: 203.

In another aspect, the disclosure provides a binding molecule comprising at least one antigen binding site that binds specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and at least one antigen binding site that binds specifically to cadherin-17 (CDH17); wherein the molecule is bispecific and tetravalent; wherein the at least one antigen binding site that binds specifically to cadherin-17 (CDH17) is an immunoglobulin (Ig) molecule and the at least one antigen binding site that binds specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) comprises one or more scFv(s); and wherein the one or more scFv(s) is fused to the C-terminus of the heavy chain of the Ig molecule, wherein the binding molecule comprises (i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 189, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 190, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 191, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 193, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 194, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 196, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 197, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 198, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 199, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 200, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 201, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 202, and (ii) a light chain comprising the amino acid sequence of SEQ ID NO: 203.

The disclosure provides a binding molecule having (i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 204, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 205, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 206, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 207, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 208, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 209, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 210, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 211, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 212, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 213, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 214, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 215, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 216, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 217; or a heavy chain comprising the amino acid sequence of SEQ ID NO: 271 and (ii) a light chain comprising the amino acid sequence of SEQ ID NO: 218.

In another aspect, the disclosure provides a binding molecule comprising at least one antigen binding site that binds specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and at least one antigen binding site that binds specifically to cadherin-17 (CDH17); wherein the molecule is bispecific and tetravalent; wherein the at least one antigen binding site that binds specifically to cadherin-17 (CDH17) is an immunoglobulin (Ig) molecule and the at least one antigen binding site that binds specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) comprises one or more scFv(s); and wherein the one or more scFv(s) is fused to the C-terminus of the heavy chain of the Ig molecule, wherein the binding molecule comprises (i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 204, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 205, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 206, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 208, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 209, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 211, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 212, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 213, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 214, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 215, or a heavy chain

comprising the amino acid sequence of SEQ ID NO: 216, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 217; or a heavy chain comprising the amino acid sequence of SEQ ID NO: 271 and (ii) a light chain comprising the amino acid sequence of SEQ ID NO: 218.

5

The disclosure provides a binding molecule having (i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 145, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 147, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 149, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 151, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 153, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 155, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 157, or a heavy chain comprising the amino acid

10

sequence of SEQ ID NO: 219, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 220, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 221, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 222, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 223, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 224, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 225; or a heavy chain comprising the amino acid sequence of SEQ ID NO: 226, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 227, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 228, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 229, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 230, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 231, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 232 and (ii) a light chain comprising the amino acid sequence of SEQ ID NO: 233.

In another aspect, the disclosure provides a binding molecule comprising at least one antigen binding site that binds specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and at least one antigen binding site that binds specifically to cadherin-17 (CDH17); wherein the molecule is bispecific and tetravalent; wherein the at least one antigen binding site that binds specifically to cadherin-17 (CDH17) is an immunoglobulin (Ig) molecule and the at least one antigen binding site that binds specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) comprises one or more scFv(s); and wherein the one or more scFv(s) is fused to the C-terminus of the heavy chain of the Ig molecule, wherein the binding molecule comprises (i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 145, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 147, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 149, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 151, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 153, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 155, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 157, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 219, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 220, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 221, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 223, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 224, or a heavy chain comprising the amino acid

sequence of SEQ ID NO: 226, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 227, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 228, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 229, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 230, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 231, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 232 and (ii) a light chain comprising the amino acid sequence of SEQ ID NO: 233.

A further aspect of the disclosure refers to an isolated nucleic acid molecule encoding the heavy chain variable domain and/or the light chain variable domain of a binding molecule as defined herein.

A further aspect of the disclosure refers to an isolated nucleic acid molecule encoding the heavy chain and/or the light chain of a binding molecule as defined herein.

A further aspect of the disclosure refers to an expression vector comprising a nucleic acid molecule as defined herein.

A further example of the disclosure provides a nucleic acid molecule encoding a binding molecule of the disclosure or an expression vector containing such a nucleic acid molecule.

A further aspect of the disclosure refers to a host cell transfected with an expression vector as defined herein.

A further example of the disclosure provides a host cell comprising a nucleic acid molecule of the disclosure in functional association with an expression control sequence. Further provided herein is a host cell comprising an expression vector comprising a nucleic acid molecule encoding a binding molecule as described herein.

A further example of the disclosure provides a method of production of a binding molecule of the invention, comprising

(a) cultivating the host cell of the disclosure under conditions allowing expression of the molecule; and,

(b) recovering the molecule.

5 A further aspect of the disclosure refers to a method of manufacturing a binding molecule as defined herein, comprising

(a) cultivating the host cell as defined herein under conditions allowing expression of the molecule; and,

(b) recovering the molecule; and optionally,

10 (c) further purifying and/or modifying and/or formulating the molecule.

A further aspect of the disclosure refers to a binding molecule as defined herein for use in medicine.

15 A further aspect of the disclosure refers to use of the binding molecule as defined herein in the manufacture of a pharmaceutical composition for treating cancer.

A further aspect of the disclosure refers to a binding molecule as defined herein for use in treating cancer.

20

A further example of the disclosure provides a binding molecule of the disclosure, for use in the therapy of cancer, preferably colorectal cancer (CRC), gastric cancer (GC), pancreatic cancer (PAC), Esophageal cancer or neuroendocrine tumors.

CLAIMS

1. A binding molecule comprising at least one antigen binding site that binds specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and at least one antigen binding site that binds specifically to cadherin-17 (CDH17); wherein the molecule is bispecific and tetravalent; wherein the at least one antigen binding site that binds specifically to cadherin-17 (CDH17) is an immunoglobulin (Ig) molecule and the at least one antigen binding site that binds specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) comprises one or more scFv(s); and wherein the one or more scFv(s) is fused to the C-terminus of the heavy chain of the Ig molecule.
2. The binding molecule of claim 1, wherein the one or more scFv(s) have a VL-VH orientation from N-to C-terminus.
3. The binding molecule of claim 1 or 2, wherein the Ig molecule is IgG.
4. The binding molecule of any one of claims 1 to 3, wherein the one or more scFv(s) is fused to the Ig molecule by a peptide linker, preferably a peptide linker having a length of about 4 to 20 amino acids.
5. The binding molecule of any one of claims 1 to 4, wherein the antigen binding site that binds specifically to TRAILR2 is selected from the group consisting of antigen binding sites:
 - i) to xi)
- i) an antigen binding site comprising heavy chain CDRs comprising the amino acid sequences of SEQ ID NO.:1 (CDR1), SEQ ID NO.:2 (CDR2) and SEQ ID NO.:3 (CDR3) and light chain CDRs comprising the amino acid sequences of SEQ ID NO.:4 (CDR1), SEQ ID NO.:5 (CDR2) and SEQ ID NO.:6 (CDR3);
- ii) an antigen binding site comprising heavy chain CDRs comprising the amino acid sequences of SEQ ID NO.:7 (CDR1), SEQ ID NO.:8 (CDR2) and SEQ ID NO.:9 (CDR3) and light chain CDRs comprising the amino acid sequences of SEQ ID NO.:10 (CDR1), SEQ ID NO.11 (CDR2) and SEQ ID NO.:12 (CDR3);

iii) an antigen binding site comprising heavy chain CDRs comprising the amino acid sequences of SEQ ID NO.:13 (CDR1), SEQ ID NO.:14 (CDR2) and SEQ ID NO.:15 (CDR3) and light chain CDRs comprising the amino acid sequences of SEQ ID NO.:16 (CDR1), SEQ ID NO.17 (CDR2) and SEQ ID NO.:18 (CDR3);

5

iv) an antigen binding site comprising heavy chain CDRs comprising the amino acid sequences of SEQ ID NO.:25 (CDR1), SEQ ID NO.:26 (CDR2) and SEQ ID NO.:27 (CDR3) and light chain CDRs comprising the amino acid sequences of SEQ ID NO.:28 (CDR1), SEQ ID NO.29 (CDR2) and SEQ ID NO.:30 (CDR3);

10

v) an antigen binding site comprising heavy chain CDRs comprising the amino acid sequences of SEQ ID NO.:31 (CDR1), SEQ ID NO.:32 (CDR2) and SEQ ID NO.:33 (CDR3) and light chain CDRs comprising the amino acid sequences of SEQ ID NO.:34 (CDR1), SEQ ID NO.35 (CDR2) and SEQ ID NO.:36 (CDR3);

15

vi) an antigen binding site comprising heavy chain CDRs comprising of SEQ ID NO.:43 (CDR1), SEQ ID NO.:44 (CDR2) and SEQ ID NO.:48 (CDR3) and light chain CDRs comprising the amino acid sequences of SEQ ID NO.:49 (CDR1), SEQ ID NO.50 (CDR2) and SEQ ID NO.:54 (CDR3);

20

vii) an antigen binding site comprising heavy chain CDRs comprising of SEQ ID NO.:43 (CDR1), SEQ ID NO.:45 (CDR2) and SEQ ID NO.:48 (CDR3) and light chain CDRs comprising the amino acid sequences of SEQ ID NO.:49 (CDR1), SEQ ID NO.51 (CDR2) and SEQ ID NO.:55 (CDR3);

25

viii) an antigen binding site comprising heavy chain CDRs comprising of SEQ ID NO.:43 (CDR1), SEQ ID NO.:45 (CDR2) and SEQ ID NO.:48 (CDR3) and light chain CDRs comprising the amino acid sequences of SEQ ID NO.:49 (CDR1), SEQ ID NO.52 (CDR2) and SEQ ID NO.:56 (CDR3);

30

ix) an antigen binding site comprising heavy chain CDRs comprising of SEQ ID NO.:43 (CDR1), SEQ ID NO.:45 (CDR2) and SEQ ID NO.:48 (CDR3) and light chain CDRs comprising the amino acid sequences of SEQ ID NO.:49 (CDR1), SEQ ID NO.50 (CDR2) and SEQ ID NO.:56 (CDR3);

x) an antigen binding site comprising heavy chain CDRs comprising of SEQ ID NO.:43 (CDR1), SEQ ID NO.:46 (CDR2) and SEQ ID NO.:48 (CDR3) and light chain CDRs comprising the amino acid sequences of SEQ ID NO.:49 (CDR1), SEQ ID NO.51 (CDR2) and SEQ ID NO.:57 (CDR3); and

xi) an antigen binding site comprising heavy chain CDRs comprising of SEQ ID NO.:43 (CDR1), SEQ ID NO.:47 (CDR2) and SEQ ID NO.:48 (CDR3) and light chain CDRs comprising the amino acid sequences of SEQ ID NO.:49 (CDR1), SEQ ID NO.53 (CDR2) and SEQ ID NO.:57 (CDR3).

6. The binding molecule of any one of claims 1 to 5, wherein the antigen binding site that binds specifically to TRAILR2 is selected from the group consisting of antigen binding sites i) to xii):

i) an antigen binding site comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO.:82 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO.:83;

ii) an antigen binding site comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO.:84 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO.:85;

iii) an antigen binding site comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO.:86 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO.:87;

iv) an antigen binding site comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO.:90 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO.:91;

v) an antigen binding site comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO.:92 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO.:93;

vi) an antigen binding site comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO.:96 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO.:97;

5

vii) an antigen binding site comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO.:98 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO.:99;

10

viii) an antigen binding site comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO.:100 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO.:101;

15

ix) an antigen binding site comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO.:102 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO.:103;

20

x) an antigen binding site comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO.:104 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO.:105;

25

xi) an antigen binding site comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO.:106 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO.:107; and

xii) an antigen binding site comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO.:108 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO.:109.

30

7. The binding molecule of any one of claims 1 to 6, wherein the antigen binding site that binds specifically to CDH17 is selected from the group consisting of antigen binding sites i) to iv):

i) an antigen binding site comprising heavy chain CDRs comprising the amino acid sequences of SEQ ID NO.:58 (CDR1), SEQ ID NO.:59 (CDR2) and SEQ ID NO.:60 (CDR3) and light chain CDRs comprising the amino acid sequences of SEQ ID NO.:61 (CDR1), SEQ ID NO.62 (CDR2) and SEQ ID NO.:63 (CDR3);

5

ii) an antigen binding site comprising heavy chain CDRs comprising the amino acid sequences of SEQ ID NO.:64 (CDR1), SEQ ID NO.:65 (CDR2) and SEQ ID NO.:66 (CDR3) and light chain CDRs comprising the amino acid sequences of SEQ ID NO.:67 (CDR1), SEQ ID NO.68 (CDR2) and SEQ ID NO.:69 (CDR3);

10

iii) an antigen binding site comprising heavy chain CDRs comprising the amino acid sequences of SEQ ID NO.:70 (CDR1), SEQ ID NO.:71 (CDR2) and SEQ ID NO.:72 (CDR3) and light chain CDRs comprising the amino acid sequences of SEQ ID NO.:73 (CDR1), SEQ ID NO.74 (CDR2) and SEQ ID NO.:75 (CDR3); and,

15

iv) an antigen binding site comprising heavy chain CDRs comprising the amino acid sequences of SEQ ID NO.:76 (CDR1), SEQ ID NO.:77 (CDR2) and SEQ ID NO.:78 (CDR3) and light chain CDRs comprising the amino acid sequences of SEQ ID NO.:79 (CDR1), SEQ ID NO.80 (CDR2) and SEQ ID NO.:81 (CDR3).

20

8. The binding molecule of any one of claims 1 to 7, wherein the antigen binding site binding site that binds specifically to CDH17 is selected from the group consisting of antigen binding sites i) to v):

25

i) an antigen binding site comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO.:110 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO.:111;

30

ii) an antigen binding site comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO.:112 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO.:113;

iii) an antigen binding site comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO.:114 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO.:115;

iv) an antigen binding site comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO.:116 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO.:117; and,

v) an antigen binding site comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO.:118 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO.:119.

9. A binding molecule comprising at least one antigen binding site that binds specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and at least one antigen binding site that binds specifically to cadherin-17 (CDH17); wherein the molecule is bispecific and tetravalent; wherein the at least one antigen binding site that binds specifically to cadherin-17 (CDH17) is an immunoglobulin (Ig) molecule and the at least one antigen binding site that binds specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) comprises one or more scFv(s); and wherein the one or more scFv(s) is fused to the C-terminus of the heavy chain of the Ig molecule,

wherein the binding molecule comprises (i) a heavy chain comprising the amino acid sequence of SEQ ID NO. 159, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 160, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 161, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 163, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 164, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 166, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 167, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 168, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 169, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 170, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 171, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 172, and (ii) a light chain comprising the amino acid sequence of SEQ ID NO. 173.

10. A binding molecule comprising at least one antigen binding site that binds specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and at least one antigen binding site that binds specifically to cadherin-17 (CDH17); wherein the molecule is bispecific and tetravalent; wherein the at least one antigen binding site that binds specifically to cadherin-17 (CDH17) is an immunoglobulin (Ig) molecule and the at least one antigen binding site that binds specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) comprises one or more scFv(s); and wherein the one or more scFv(s) is fused to the C-terminus of the heavy chain of the Ig molecule,

wherein the binding molecule comprises (i) a heavy chain comprising the amino acid sequence of SEQ ID NO. 174, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 175, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 176, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 178, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 179, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 181, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 182, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 183, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 184, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 185, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 186, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 187, and (ii) a light chain comprising the amino acid sequence of SEQ ID NO. 188.

11. A binding molecule comprising at least one antigen binding site that binds specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and at least one antigen binding site that binds specifically to cadherin-17 (CDH17); wherein the molecule is bispecific and tetravalent; wherein the at least one antigen binding site that binds specifically to cadherin-17 (CDH17) is an immunoglobulin (Ig) molecule and the at least one antigen binding site that binds specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) comprises one or more scFv(s); and wherein the one or more scFv(s) is fused to the C-terminus of the heavy chain of the Ig molecule,

wherein the binding molecule comprises (i) a heavy chain comprising the amino acid sequence of SEQ ID NO. 189, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 190, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 191, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 193, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 194, or a heavy chain comprising the

amino acid sequence of SEQ ID NO. 196, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 197, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 198, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 200, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 201, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 202, and (ii) a light chain comprising the amino acid sequence of SEQ ID NO. 203.

12. A binding molecule comprising at least one antigen binding site that binds specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and at least one antigen binding site that binds specifically to cadherin-17 (CDH17); wherein the molecule is bispecific and tetravalent; wherein the at least one antigen binding site that binds specifically to cadherin-17 (CDH17) is an immunoglobulin (Ig) molecule and the at least one antigen binding site that binds specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) comprises one or more scFv(s); and wherein the one or more scFv(s) is fused to the C-terminus of the heavy chain of the Ig molecule,

wherein the binding molecule comprises (i) a heavy chain comprising the amino acid sequence of SEQ ID NO. 204, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 205, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 206, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 208, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 209, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 211, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 212, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 213, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 214, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 215, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 216, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 217; and (ii) a light chain comprising the amino acid sequence of SEQ ID NO. 218.

13. A binding molecule comprising at least one antigen binding site that binds specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and at least one antigen binding site that binds specifically to cadherin-17 (CDH17); wherein the molecule is bispecific and tetravalent; wherein the at least one antigen binding site that binds specifically to cadherin-17 (CDH17) is an immunoglobulin (Ig) molecule and the at least one antigen

binding site that binds specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) comprises one or more scFv(s); and wherein the one or more scFv(s) is fused to the C-terminus of the heavy chain of the Ig molecule,

wherein the binding molecule comprises (i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 145, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 147, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 149, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 151, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 153, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 155, or a heavy chain comprising the amino acid sequence of SEQ ID NO: 157, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 219, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 220, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 221, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 223, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 224, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 226, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 227, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 228, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 229, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 230, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 231, or a heavy chain comprising the amino acid sequence of SEQ ID NO. 232; and (ii) a light chain comprising the amino acid sequence of SEQ ID NO. 233.

14. An isolated nucleic acid molecule encoding the heavy chain variable domain and the light chain variable domain of a binding molecule of any one of claims 5 to 8.

15. An isolated nucleic acid molecule encoding the heavy chain and the light chain of a binding molecule of any one of claims 9 to 13.

16. An expression vector comprising a nucleic acid molecule of claim 14 or 15.

17. A host cell transfected with an expression vector of claim 16.

18. A method of manufacturing a binding molecule of any one of claims 5 to 13 comprising

- (a) cultivating the host cell of claim 17 under conditions allowing expression of the molecule; and,
- (b) recovering the molecule; and optionally
- c) further purifying and/or modifying and/or formulating the molecule.

5

19. The binding molecule of any one of claims 1 to 13 for use in medicine.

20. A pharmaceutical composition comprising a binding molecule of any one of claims 1 to 13 and a pharmaceutically acceptable carrier.

10

21. Use of the binding molecule of any one of claims 1 to 13 in the manufacture of a pharmaceutical composition for treating cancer.

22. The binding molecule of any one of claims 1 to 13 for use in treating cancer.

15

23. The use of claim 21 or the binding molecule for use of claim 22, wherein the cancer is colorectal cancer (CRC), gastric cancer (GC), pancreatic cancer (PAC), esophageal cancer or a neuroendocrine tumor.

20